Table 2.

Relationship between MUC20 or SPRR1B expression and clinicopathological parameters

Parameters	MUC20		SPRR1B
	Negative	Positive	Negative	Positive
Gender
Male	94	38	46	86
Female	55	26	31	50
P value	0.6458		0.6605
Age
< −65	53	25	24	54
> 65	96	39	53	82
P value	0.6443		0.2384
Site
Tongue	94	43	46	91
Other	55	21	31	45
P value	0.6408		0.3017
Histological differentiationa
Well	85	38	35	88
Mod, por	64	26	42	48
P value	0.7649		0.0091
T classification
T1–T2	81	27	44	64
T3–T4	68	37	33	72
P value	0.1347		0.1991
Clinical stage
I–II	70	16	37	49
IIII–IV	79	48	40	87
P value	0.0036		0.1097
Tumor size
< –4 cm	87	35	48	74
> 4 cm	62	29	29	62
P value	0.6521		0.3131
Invasive depth
< − 10 mm	92	33	50	75
> 10 mm	57	31	27	61
P value	0.1753		0.1930
Nodal metastasis
Negative	99	28	48	79
Positive	50	36	29	57
P value	0.0021		0.5643
MVDb	14.665 ± 5.983	20.011 ± 4.695	15.857 ± 5.147	16.506 ± 6.628
P value	< 0.0001		0.4593
LVDc	12.145 ± 5.152	17.506 ± 4.148	13.638 ± 5.121	13.823 ± 5.647
P value	< 0.0001		0.8214

Relationship between expression of MUC20 or SPRR1B and parameters were calculated by Fisher’s exact test or student’s t test. T classification and clinical stage were classified according to the TNM classification

^aHistological differentiation: Well, well-differentiated squamous cell carcinoma; Mod, moderately differentiated squamous cell carcinoma; Por, poorly differentiated squamous cell carcinoma

^bMVD means micro-vessel density

^cLVD means lympho vessel density